{Reference Type}: Journal Article
{Title}: Serum miR-181a and miR-25 in patients with malignant and benign breast diseases.
{Author}: Perepechaeva ML;Studenikina AA;Grishanova AY;Glushkov AN;Polenok EG;Bajramov PV;Autenshlyus AI;
{Journal}: Biomed Khim
{Volume}: 69
{Issue}: 5
{Year}: 2023 Nov
暂无{DOI}: 10.18097/PBMC20236905307
{Abstract}: Breast tumor diseases include a wide range of pathologies that require different approaches to their treatment. MicroRNA (miR) levels, reflecting regulation of the gene expression involved in tumorigenesis, can be diagnostic and prognostic markers of breast diseases. The levels of circulating miR-181a and miR-25 were measured in patients with benign breast diseases (BBD), patients with invasive carcinoma of a nonspecific type (ICNT) and also in conditionally healthy women. Expression of both miRs was higher in patients of both groups as compared to controls; at the same time, the content of serum miR-181a and miR-25 was higher in BBD patients than in ICNT patients. The detected changes may be of interest in the context of precancerous changes in BBD. It seems possible to use them in the future as markers of the pathological process as a part of a large diagnostic panel.